CD-36 variants and circulating miRNAs as prognostic biomarkers and potential therapeutic targets in breast cancer patients

The influence of the CD-36 variant on the susceptibility to breast cancer (BC) and correlations between miRNA-375 / CD-36 axes and breast cancer is still not fully determined. The current study aimed to determine the impact of CD-36 rs1761667 and rs1527483 presence of breast cancer and its prognosis, as well as the relationship between these variants and miRNA-375 and miRNA-155 expression levels as potential biomarkers for BC. Overall, 176 individuals were enrolled in this study, 48 patients with metastatic BC, 50 patients with non-metastatic BC, 43 patients with benign BC, and 35 healthy volunteers. Genotyping and serum expression profiles were assessed using qPCR, and CD-36 was measured by ELISA. The genotype AA of rs1761667 was associated with increased BC occurrence. Serum CD-36 was significantly increased in metastatic BC patients versus healthy controls. In addition, miRNA-155 and miRNA-375 were upregulated in BC. The current study demonstrates that miRNA-375 and CD-36 have the potential to be used as non-invasive prognostic biomarkers for BC.